Abstract
Evidence has indicated that endothelin-1 is related to the pathogenesis of hypertension. To characterize the role of endothelin-1 (ET-1) in the development of pulmonary hypertension syndrome in broilers, the blockade effect of $ET_A$ receptor antagonist, BQ123, on blood pressure in experimental models of pulmonary hypertension was examined. Birds were exposed to low ambient temperature for 7 or 14 days. In treated groups, BQ123 (0.4 or 2.0 μg each time, twice daily) administered for 7 or 14 days prevented both pulmonary arterial pressure (PAP) and right ventricular pressure (RVP) increases. High-dose BQ123 lowered PAP and RVP to normotensive levels comparable to controls at normal temperatures. Furthermore, there was a reduction in cold-induced right ventricular hypertrophy. The preventive effect of BQ123 suggests that ET-1 is associated with the development of broiler pulmonary hypertension and subsequent ascites.
Introduction
Modern broiler chickens are genetically selected for rapid growth, which demands high oxygen consumption. Environmental stressors, particularly low ambient temperatures, increase metabolic heat production and oxygen requirements. When the cardiovascular system cannot meet this demand, pulmonary hypertension (PH) develops. Chronic PH leads to right ventricular hypertrophy and eventually heart failure, a condition known as Pulmonary Hypertension Syndrome (PHS) or ascites. While Endothelin-1 (ET-1) is a potent vasoconstrictor, its specific role in avian PHS required further investigation. This study explores whether blocking the $ET_A$ receptor can prevent the onset of this syndrome.
Methods
Day-old male broiler chicks (Arbor Acre strain) were divided into six groups to test the efficacy of BQ123, a selective $ET_A$ receptor antagonist:
- N.C: Normal temperature control (28°C).
- N.BQ123: Normal temperature + BQ123.
- L.C: Low temperature control (15–18°C).
- L.Saline: Low temperature + saline injection.
- L.BQ123/0.4: Low temperature + 0.4 μg BQ123.
- L.BQ123/2.0: Low temperature + 2.0 μg BQ123.
BQ123 was administered via abdominal injection twice daily. Researchers measured Pulmonary Arterial Pressure (PAP), Right Ventricular Pressure (RVP), Ascites Heart Index (AHI), and Packed Cell Volume (PCV) to assess physiological and morphological changes.
Results
The experimental data confirmed that cold stress is a potent trigger for hypertension and heart remodeling, both of which were significantly mitigated by BQ123 treatment.
Pulmonary Pressure and Heart Health
In cold-stressed birds (L.C and L.Saline), PAP rose significantly to approximately 4.68 kPa. Treatment with high-dose BQ123 (2.0 μg) maintained PAP at approximately 2.99 kPa, which is nearly identical to the normotensive levels seen in the control group.
Beyond pressure regulation, the antagonist prevented pathological remodeling of the heart. The Ascites Heart Index (AHI), a measure of right ventricular hypertrophy, reached ~30% in untreated cold-stressed birds but remained at ~20% in the BQ123-treated groups, matching healthy controls.
Blood Viscosity and Heart Rate
Cold stress typically increases Packed Cell Volume (PCV), making blood more viscous and harder to pump. PCV increased from ~34% to over 40% in stressed birds, but BQ123 treatment limited this rise to 32-34%. Additionally, BQ123 helped mitigate the decline in heart rate typically observed under cold stress compared to saline-treated counterparts.
Discussion
This study identifies ET-1 as a primary mediator in the development of cold-induced pulmonary hypertension in broilers. By successfully blocking the $ET_A$ receptor, the researchers prevented the physiological and structural progression toward ascites.
While these results are promising, practical application in commercial poultry farming faces challenges. Twice-daily abdominal injections are not feasible for large-scale operations. Future research should focus on more practical delivery methods, such as oral administration or long-acting formulations. Furthermore, understanding this pathway provides a potential biomarker for genetic selection, allowing for the breeding of birds naturally resistant to cold-induced hypertension.
Summary updated